WO2005047512A3 - Plasmid system for multigene expression - Google Patents

Plasmid system for multigene expression Download PDF

Info

Publication number
WO2005047512A3
WO2005047512A3 PCT/US2004/037721 US2004037721W WO2005047512A3 WO 2005047512 A3 WO2005047512 A3 WO 2005047512A3 US 2004037721 W US2004037721 W US 2004037721W WO 2005047512 A3 WO2005047512 A3 WO 2005047512A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasmid system
multigene expression
plasmid
multigene
expression
Prior art date
Application number
PCT/US2004/037721
Other languages
French (fr)
Other versions
WO2005047512A2 (en
Inventor
Deba P Saha
Original Assignee
Schering Corp
Deba P Saha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Deba P Saha filed Critical Schering Corp
Priority to JP2006539876A priority Critical patent/JP2007510434A/en
Priority to AT04810783T priority patent/ATE514783T1/en
Priority to EP04810783A priority patent/EP1694850B1/en
Priority to CA002545755A priority patent/CA2545755A1/en
Publication of WO2005047512A2 publication Critical patent/WO2005047512A2/en
Publication of WO2005047512A3 publication Critical patent/WO2005047512A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate may independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors.
PCT/US2004/037721 2003-11-12 2004-11-10 Plasmid system for multigene expression WO2005047512A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006539876A JP2007510434A (en) 2003-11-12 2004-11-10 A plasmid system for multigene expression.
AT04810783T ATE514783T1 (en) 2003-11-12 2004-11-10 PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
EP04810783A EP1694850B1 (en) 2003-11-12 2004-11-10 Plasmid system for multigene expression
CA002545755A CA2545755A1 (en) 2003-11-12 2004-11-10 Plasmid system for multigene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51923003P 2003-11-12 2003-11-12
US60/519,230 2003-11-12

Publications (2)

Publication Number Publication Date
WO2005047512A2 WO2005047512A2 (en) 2005-05-26
WO2005047512A3 true WO2005047512A3 (en) 2005-06-23

Family

ID=34590376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037721 WO2005047512A2 (en) 2003-11-12 2004-11-10 Plasmid system for multigene expression

Country Status (8)

Country Link
US (3) US7326567B2 (en)
EP (1) EP1694850B1 (en)
JP (2) JP2007510434A (en)
CN (1) CN1938428A (en)
AT (1) ATE514783T1 (en)
CA (1) CA2545755A1 (en)
WO (1) WO2005047512A2 (en)
ZA (1) ZA200603731B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US20080050808A1 (en) * 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
US7785871B2 (en) * 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
WO2005116231A1 (en) 2004-05-18 2005-12-08 Intrexon Corporation Methods for dynamic vector assembly of dna cloning vector plasmids
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
WO2006060419A2 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
JP2008543283A (en) * 2005-06-10 2008-12-04 ジェネンテック・インコーポレーテッド Improving antibody expression using vectors containing insulator elements
EP2468881A3 (en) 2005-07-21 2012-08-15 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US8153598B2 (en) * 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
EP2032989B2 (en) * 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2 biomarker
AU2008233196B2 (en) * 2007-03-30 2011-10-13 Abbvie Inc. Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
KR101030978B1 (en) * 2008-07-10 2011-04-28 (주) 에이프로젠 Recombinant Expression Vectors for Animal Cells
AU2009280913A1 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
WO2010049777A1 (en) * 2008-10-28 2010-05-06 Avesthagen Limited An expression vector and processes thereof
JP2012508563A (en) * 2008-11-12 2012-04-12 シェーリング コーポレイション ΒG1-IGG intron for enhanced anti-IGF1R expression
US8137933B2 (en) 2008-11-12 2012-03-20 Schering Corporation Mammalian expression vector pUHAB
WO2011015917A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant tnk-tpa (tenecteplase)
WO2011015916A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant infliximab
WO2011015918A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant cetuximab
WO2011015924A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant trastuzumab
TWI688395B (en) 2010-03-23 2020-03-21 英翠克頌公司 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
EP2694655A4 (en) * 2011-04-08 2015-01-14 Merck Sharp & Dohme pAVEC
MX353958B (en) 2011-09-22 2018-02-07 Amgen Inc Cd27l antigen binding proteins.
WO2013078433A1 (en) 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
CN102559750B (en) * 2011-11-25 2014-03-12 佛山安普泽生物医药有限公司 Efficient expression vector of antibody and preparation method for efficient expression vector
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
CN102703498A (en) * 2012-06-04 2012-10-03 河北农业大学 Multi-gene plant expression vector and construction method as well as application thereof
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EA201592285A1 (en) 2013-05-30 2016-05-31 Байоджен Ма Инк. ANTIGENSYCLING PROTEINS TO ONCOSTATIN M RECEPTOR
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX2017012966A (en) 2015-04-10 2018-06-06 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells.
CN107787332B (en) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 Multispecific antigen binding proteins
CA2996691A1 (en) 2015-09-22 2017-03-30 Genentech, Inc. Expression of fc-containing proteins
CA3000869A1 (en) 2015-10-08 2017-04-13 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
SG11201802773RA (en) 2015-11-02 2018-05-30 Genentech Inc Methods of making fucosylated and afucosylated forms of a protein
KR20180133198A (en) 2016-05-04 2018-12-13 암젠 인크 Interleukin-2 mutein for proliferation of T-regulatory cells
BR112019025105A2 (en) 2017-06-30 2020-10-20 Zymeworks Inc. stabilized chimeric fabs
CA3092069C (en) 2018-02-27 2022-08-30 Mascull, Roger Thomas A seating support
US20220267802A1 (en) * 2019-07-15 2022-08-25 President And Fellows Of Harvard College Methods and compositions for gene delivery
MX2022001866A (en) 2019-08-13 2022-03-11 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells.
CN112941028A (en) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 Nano antibody gene modified mesenchymal stem cell and preparation method and application thereof
JP2023507115A (en) 2019-12-17 2023-02-21 アムジエン・インコーポレーテツド Dual interleukin-2/TNF receptor agonist for use in therapy
CN116284442B (en) * 2023-02-08 2023-10-17 中国农业科学院生物技术研究所 Fusion protein for controlling leaf color and application of fusion protein in research on interaction of plant transcription factors and DNA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088121A1 (en) * 2000-05-19 2001-11-22 Devgen Nv Vector constructs
WO2002014525A2 (en) * 2000-07-29 2002-02-21 Mogam Biotechnology Research Institute Expression vector using for animal cell

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
AU7444191A (en) 1990-02-28 1991-09-18 Schering Corporation Mammalian expression vectors
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JPH04166089A (en) * 1990-10-30 1992-06-11 Eiken Chem Co Ltd Plasmid vector for immunoglobulin gene expression and recombination of v-portion gene using the same
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5262308A (en) 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
WO1994023034A2 (en) 1993-04-06 1994-10-13 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
US20020022023A1 (en) 1999-01-15 2002-02-21 Axel Ullrich Treatment of diabetes mellitus and insulin receptor signal transduction
JP3946256B2 (en) * 1995-09-11 2007-07-18 協和醗酵工業株式会社 Antibody to human interleukin 5 receptor α chain
US6084085A (en) 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US20020187925A1 (en) 1996-05-22 2002-12-12 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
ZA979295B (en) 1996-10-18 1998-04-20 Canji Inc Methods and compositions for delivery and expression of interferon-Ó nucleic acids.
US20020155095A1 (en) 1996-10-18 2002-10-24 Tattanahalli L. Nagabhushan Methods and compositions for delivery and expression of interferon-a nucleic acids
WO1998022092A1 (en) 1996-11-22 1998-05-28 The Regents Of The University Of California Transport of liposomes across the blood-brain barrier
US6399789B1 (en) * 1996-12-18 2002-06-04 Kosan Biosciences, Inc. Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
TW562807B (en) * 1997-04-01 2003-11-21 Chugai Pharmaceutical Co Ltd Novel secretory membrane protein
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JPH1132779A (en) * 1997-07-24 1999-02-09 Fujita Gakuen Gene cloning of protein
CA2310269A1 (en) 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999028347A1 (en) 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
WO1999042127A2 (en) 1998-02-24 1999-08-26 Receptron, Inc. Receptor derived peptides as modulators of receptor activity
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
MXPA00011248A (en) 1998-05-15 2004-09-06 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
AU3579200A (en) 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6511967B1 (en) * 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
EP1228237A1 (en) * 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
WO2001036632A2 (en) 1999-11-17 2001-05-25 Compugen Ltd. Variants of alternative splicing
WO2001044464A1 (en) 1999-12-15 2001-06-21 Mcgill University Targeting of endosomal growth factor processing as anti-cancer therapy
AU2001245888A1 (en) 2000-03-21 2001-10-03 University Of South Florida Growth factor binding molecules
JP2003527441A (en) 2000-03-22 2003-09-16 グラクソ グループ リミテッド Drugs that block cell cycle and drugs that contain antibodies
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2004512010A (en) 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー Insulin and IGF-1 receptor agonists and antagonists
AU5521401A (en) 2000-03-31 2001-10-15 Hyseq Inc Method and materials relating to insulin-like growth factor binding protein-likepolypeptides and polynucleotides
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US7329745B2 (en) 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20020164333A1 (en) 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
CA2414272A1 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2002007783A2 (en) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
DE10050338A1 (en) 2000-10-11 2002-04-25 Deutsches Krebsforsch Diagnosing and staging of cancer, especially of breast, by measuring levels of insulin receptor substrate-1 or insulin-like growth factor-1 receptor beta
AU2002213196A1 (en) 2000-10-12 2002-04-22 Icos Corporation Modulation of ligand binding/enzymatic activity of alpha beta proteins
WO2002039121A2 (en) 2000-11-03 2002-05-16 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
US20020111290A1 (en) 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
ATE444488T1 (en) 2000-12-14 2009-10-15 Burnham Inst NON-APOPTOTIC FORMS OF CELL DEATH AND METHOD FOR MODULATION
AR032028A1 (en) 2001-01-05 2003-10-22 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
JP4117731B2 (en) 2001-03-14 2008-07-16 ジェネンテック・インコーポレーテッド IGF antagonist peptide
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
FR2824076B1 (en) 2001-04-27 2003-06-13 Centre Nat Rech Scient METHOD OF DETECTING ACTIVATORS OR INHIBITORS OF RECEPTORS OF THE INSULIN RECEPTOR FAMILY USING AN ISOLATED CHIMERIC RECEPTOR
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003000928A2 (en) 2001-06-25 2003-01-03 Buadbo Aps Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
IL160091A0 (en) 2001-08-06 2004-06-20 Stil Biotechnologies Ltd Methods of identifying functional analogs of peptide regulators of biological pathways
AUPR870501A0 (en) 2001-11-07 2001-11-29 Biotech Research Ventures Pte Limited Composition containing a flavonoid glycone and method for using same as anti-proliferative
JP4606739B2 (en) 2002-01-18 2011-01-05 ピエール、ファーブル、メディカマン Novel anti-IGF-IR antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
FR2834900B1 (en) 2002-01-18 2005-07-01 Pf Medicament NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
FR2834991B1 (en) 2002-01-18 2004-12-31 Pf Medicament NEW ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
FR2834990A1 (en) 2002-01-18 2003-07-25 Pf Medicament New antibodies that bind to human insulin-like growth factor receptor, useful for treatment, prevention and diagnosis of cancers
WO2003088910A2 (en) 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US7655397B2 (en) 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US20040086511A1 (en) 2002-07-12 2004-05-06 The Johns Hopkins University Neuronal gene expression patterns
US20040142381A1 (en) 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20040047835A1 (en) 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US20030138430A1 (en) 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
NZ540971A (en) 2003-02-13 2008-04-30 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP4473257B2 (en) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー Antibodies against insulin-like growth factor I receptor and uses thereof
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
KR100825156B1 (en) 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 - modified human igf-ir antibodies
DE10348391B3 (en) 2003-10-17 2004-12-23 Beru Ag Glow method for diesel engine glow plug, uses mathematical model for optimized heating of glow plug to its operating temperature
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CA2564538A1 (en) 2004-04-22 2005-12-01 Oregon Health And Science University Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
CA2573821A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド Novel tetravalent bispecific antibody
FR2873699B1 (en) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007093008A1 (en) 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088121A1 (en) * 2000-05-19 2001-11-22 Devgen Nv Vector constructs
WO2002014525A2 (en) * 2000-07-29 2002-02-21 Mogam Biotechnology Research Institute Expression vector using for animal cell

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEBBINGTON C R: "EXPRESSION OF ANTIBODY GENES IN NONLYMPHOID MAMMALIAN CELLS", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 2, no. 2, April 1991 (1991-04-01), pages 136 - 145, XP000826961, ISSN: 1046-2023 *
FLAMEZ D ET AL: "Production in Escherichia coli of a functional murine and murine::human chimeric F(ab')2 fragment and mature antibody directed against human placental alkaline phosphatase.", JOURNAL OF BIOTECHNOLOGY. 29 SEP 1995, vol. 42, no. 2, 29 September 1995 (1995-09-29), pages 133 - 143, XP002325015, ISSN: 0168-1656 *
NORDERHAUG L ET AL: "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 204, no. 1, 12 May 1997 (1997-05-12), pages 77 - 87, XP004107719, ISSN: 0022-1759 *
PAGE M J ET AL: "HIGH LEVEL EXPRESSION OF THE HUMANIZED MONOCLONAL ANTIBODY CAMPATH-1H IN CHINESE HAMSTER OVARY CELLS", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 9, no. 1, January 1991 (1991-01-01), pages 64 - 68, XP001204851, ISSN: 0733-222X *
ZHANG R ET AL: "An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.", ENDOCRINE-RELATED CANCER. DEC 2001, vol. 8, no. 4, December 2001 (2001-12-01), pages 315 - 325, XP002325014, ISSN: 1351-0088 *

Also Published As

Publication number Publication date
CN1938428A (en) 2007-03-28
US8470593B2 (en) 2013-06-25
US8062886B2 (en) 2011-11-22
ATE514783T1 (en) 2011-07-15
ZA200603731B (en) 2010-10-27
US20080311623A1 (en) 2008-12-18
CA2545755A1 (en) 2005-05-26
JP2007510434A (en) 2007-04-26
EP1694850B1 (en) 2011-06-29
EP1694850A2 (en) 2006-08-30
WO2005047512A2 (en) 2005-05-26
US7326567B2 (en) 2008-02-05
US20050176099A1 (en) 2005-08-11
JP2008061650A (en) 2008-03-21
US20120040402A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2005047512A3 (en) Plasmid system for multigene expression
NO20014534D0 (en) Method of separating proteins
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
DK1255826T3 (en) Automation of protein design for protein libraries
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
PT1257648E (en) Antagonistic selective binding agents of osteoprotegerin binding protein
WO2001047959A3 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2004007664A3 (en) Nucleic acid vectors
WO2007016715A3 (en) Immune response inducing preparations
WO2002068453A3 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
EA200600116A1 (en) OIL SUSPENSION CONCENTRATE CONTAINING DIFLUFENICAN
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2004026892A3 (en) Fragmentation of dna
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
NO20024779L (en) G protein-coupled receptor
WO2005052168A3 (en) System for the inducible expression of recombinant proteins in cyanobacteria
WO2003004678A3 (en) Novel receptors
WO2006055680A3 (en) Method for determining three-dimensional protein structure from primary protein sequence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006539876

Country of ref document: JP

Ref document number: 200603731

Country of ref document: ZA

Ref document number: 2545755

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005307

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004810783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200480040165.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004810783

Country of ref document: EP